Search research articles
Contact Us
Filters
Showing results (131-140 of 436) with videos related to
Page
of 44
Sort By:
The New England Journal of Medicine
|
July 3, 2014
New FDA breakthrough-drug category--implications for patients
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
JAMA
|
August 3, 2021
FDA Regulation and Approval of Medical Devices: 1976-2020
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
BMJ (Clinical Research Ed.)
|
October 25, 2019
Public sector financial support for late stage discovery of new drugs in the United States: cohort study
Rahul K Nayak, Jerry Avorn, Aaron S Kesselheim
Health Affairs (Project Hope)
|
July 13, 2006
The rise and fall of Natrecor for congestive heart failure: implications for drug policy
Aaron S Kesselheim, Michael A Fischer, Jerry Avorn
JAMA
|
February 21, 2022
Switching to Over-the-Counter Availability of Rescue Inhalers for Asthma
William B Feldman, Jerry Avorn, Aaron S Kesselheim
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|
November 27, 2002
Pharmaceutical cost containment with reference-based pricing: time for refinements
Sebastian Schneeweiss, Malcolm Maclure, Colin Dormuth, et al.
JAMA
|
August 8, 2013
Who is now responsible for discovering and warning about adverse effects of generic drugs?
Aaron S Kesselheim, Michael D Green, Jerry Avorn
Annals of Internal Medicine
|
December 2, 2014
Burden of changes in generic pill appearance
Aaron S Kesselheim, Niteesh K Choudhry, Jerry Avorn
The New England Journal of Medicine
|
December 7, 2017
Speed, Safety, and Industry Funding - From PDUFA I to PDUFA VI
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
JAMA Internal Medicine
|
September 12, 2017
Determinants of Market Exclusivity for Prescription Drugs in the United States
Aaron S Kesselheim, Michael S Sinha, Jerry Avorn
Page
of 44
Search research articles
Search
Showing results (131-140 of 436) with videos related to
Sort By:
Page
of 44
The New England Journal of Medicine
|
July 3, 2014
New FDA breakthrough-drug category--implications for patients
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
JAMA
|
August 3, 2021
FDA Regulation and Approval of Medical Devices: 1976-2020
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
BMJ (Clinical Research Ed.)
|
October 25, 2019
Public sector financial support for late stage discovery of new drugs in the United States: cohort study
Rahul K Nayak, Jerry Avorn, Aaron S Kesselheim
Health Affairs (Project Hope)
|
July 13, 2006
The rise and fall of Natrecor for congestive heart failure: implications for drug policy
Aaron S Kesselheim, Michael A Fischer, Jerry Avorn
JAMA
|
February 21, 2022
Switching to Over-the-Counter Availability of Rescue Inhalers for Asthma
William B Feldman, Jerry Avorn, Aaron S Kesselheim
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|
November 27, 2002
Pharmaceutical cost containment with reference-based pricing: time for refinements
Sebastian Schneeweiss, Malcolm Maclure, Colin Dormuth, et al.
JAMA
|
August 8, 2013
Who is now responsible for discovering and warning about adverse effects of generic drugs?
Aaron S Kesselheim, Michael D Green, Jerry Avorn
Annals of Internal Medicine
|
December 2, 2014
Burden of changes in generic pill appearance
Aaron S Kesselheim, Niteesh K Choudhry, Jerry Avorn
The New England Journal of Medicine
|
December 7, 2017
Speed, Safety, and Industry Funding - From PDUFA I to PDUFA VI
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
JAMA Internal Medicine
|
September 12, 2017
Determinants of Market Exclusivity for Prescription Drugs in the United States
Aaron S Kesselheim, Michael S Sinha, Jerry Avorn
Page
of 44